Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies (2006)

  • Authors:
  • USP affiliated authors: NUCCI, GILBERTO DE - ICB
  • USP Schools: ICB
  • DOI: 10.1007/s10637-006-6886-5
  • Subjects: FARMACOLOGIA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s10637-006-6886-5 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Investigational New Drugs

    ISSN: 0167-6997

    Citescore - 2017: 3.71

    SJR - 2017: 1.573

    SNIP - 2017: 0.909


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    ICB12100018940PC-ICB BMF SEP 2006
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SCHWARTSMANN, G.; DILEONE, L. P.; HOROWITZ, M.; et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs, Boston, v. 24, n. 5, p. 403-412, 2006. DOI: 10.1007/s10637-006-6886-5.
    • APA

      Schwartsmann, G., DiLeone, L. P., Horowitz, M., Schunemann, D., Cancela, A., Pereira, A. S., et al. (2006). A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs, 24( 5), 403-412. doi:10.1007/s10637-006-6886-5
    • NLM

      Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancela A, Pereira AS, Richter M, Souza F, Brondani da Rocha A, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs. 2006 ; 24( 5): 403-412.
    • Vancouver

      Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancela A, Pereira AS, Richter M, Souza F, Brondani da Rocha A, Souza FH, Pohlmann P, De Nucci G. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs. 2006 ; 24( 5): 403-412.

    Referências citadas na obra
    Ohki-Hamazaki H, Iwabuchi M, Maekawa F (2005) Development and function of bombesin-like peptides and their receptors. Int J Dev Biol 49:293–300
    Cuttitta F, Carney DN, Mulshine J, et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316:823–836
    Nelson J, Dornelly M, Walker B, Gray J, Shaw C, Murphy RF (1991) Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer 63:933–936
    Bologna M, Gestuccia C, Muzi P, Ciomei M (1989) Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 63:1714–1720
    Carney DN, Cuttitta F, Moody TW, Minna JD (1987) Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47:821–825
    Sun B, Schally AV, Halmos G (2000) The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regul Pept 90:77–84
    Qin Y, Ertl T, Cai R-Z, Halmos G, Schally AV (1994) Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res 54:1035–1041
    Hajri A, Balboni G, Koenig M, Garaud JC, Damge C (1992) Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res 52:3726–2732
    Kelley MJ, Linnoila RL, Avis IL, Georgiadis MS, Cuttita F, Mulshine JL, et al. (1997) Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256–261
    Cai R-Z, Radulovic S, Pinski J, Nagy A, Redding TW, Olsen DB, Schally AV (1992) Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides 13:267–271
    Cai R-Z, Reile H, Armatis P, Schally AV (1994) Potent BN antagonists with C-terminal LeuΨ(CH2N)Tac-NH2 or its derivatives. Proc Natl Acad Sci USA 91:12664–12668
    Pinski J, Yano T, Rekasi Z, Cai RZ, Radulovic S, Schally AV (1992) High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regul Pept 41(3):185–193
    Kiaris H, Schally AV, Sun B, Armatis P, Groot K (1999) Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene 18:7168–7173
    Yano T, Pinski J, Groot K, Schally AV (1992) Stimulation and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52:4545–4547
    Qin Y, Halmos G, Cai R-Z, Szoke B, Ertl T, Schally AV (1994) Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J Cancer Res Clin Oncol 120:519–528
    Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K (2000) Inhibition of growth of OV-1063 human epithelial ovarian cancers and c-jun and c-fos oncogene expression by bombesin antagonists. Br J Cancer 83:906–913
    Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV (1998) Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the level and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer 83:1335–1343
    Bajo AM, Schally AV, Groot K, Szepeshazi K (2004) Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 90(1):245–252
    Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE (1997) A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MTX mouse mammary cancers. Proc Natl Acad Sci USA 94:10913–10918
    Pereira AS, Di Leone L, Souza FH, Lilla S, Richter M, Schwartsmann G, De Nucci G (2005) Quantification of the bombesin/gastrin releasing peptide antagonist RC-3095 by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 816(1–2):321–32620
    Pinski J, Reile H, Halmos G, Groot K, Schally AV (1994) Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 54:169–174
    Pinski J, Halmos G, Yano T, Szepeshazi K, Qin Y, Ertl T, Schally AV (1994) Inhibition of growth of MKN-45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing peptide antagonist (RC-3095) and somatostain analog RC-160. Int J Cancer 57:574–580
    Liebow C, Crean D, Lee MT, et al. (1994) Synergistic effects of bombesin and epidermal growth factor on cancers. Proc Natl Acad Sci 91:3804–3808
    Schwartsmann G (2004) Dexamethasone and gastrin-relasing peptide receptors in human lung cells. Lung Cancer 46:129
    Radulovic S, Miller G, Schally AV (1991) Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res 51:6006–6009
    Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T (1994) Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 33:693–701
    Roesler R, Henriques JA, Schwartsmann G (2004) Neuropeptides and anxiety disorders: Bombesin receptors as novel therapeutic targets. Trends Pharmacol Sci 25:241–242
    Roesler R, Kopschina MI, Rosa RM, Henriques JA, Souza DO, Schwartsmann G (2004) RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol 13:35–41
    Roesler R, Lessa D, Venturella R, Vianna MR, Luft T, Henriques JA, Izquierdo I, Schwartsmann G (2004) Bombesin/gastrin-releasing peptide receptors in the basolateral amygdale regulate memory consolidation. Eur J Neurosci 19:1041–1045
    Shirahige Y, Cai R-Z, Szepeshazi K, Halmos G, Pinski J, Groot K, Schally AV (1994) Inhibitory effect of bombesin gastrin-releasing peptide (GRP) antagonists RC-3095-II and RC-3095 on MCF7 MIII human breast cancer xenografts in nude mice. Biomed Pharmacother 48:465–472
    Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S (1992) Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst 84:1915–1922
    Szepeshazi K, Schally AV, Groot K, Halmos G (1993) Effect of bombesin, gastrin-releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 54:282–289
    Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV (1994) Inhibitory effect of bombesin/gastrin releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer 73:1229–1238
    Ide A, Ashizawa K, Ishikawa N, Ishii R, Ando T, Abe Y, Sera N, Usa T, Tominaga T, Ejima E, Nakashima M, Ito K, Ito K, Eguchi K (2001) Elevation of serum pro-gastrin-releasing peptide in patients with medullary thyroid carcinoma and small cell lung carcinoma. Thyroid 11:1055–1061
    Weber CJ, O’Dorisio TM, Howe B, D’Agati V, Ward L, Russell J, Feind CR (1991) Vasoactive intestinal polypeptide-, neurotensin-, substance P-, gastrin-releasing peptide-, calcitonin-, calcitonin gene related peptide-, and somatostatin-like immunoreactivities in human parathyroid glands. Surgery 110(6):1078–1985